Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Germline BRCA1/2 Mutations”

42 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 42 results

Testing effectiveness (Phase 2)Study completedNCT02789332
What this trial is testing

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

Who this might be right for
Breast CancerTriple Negative Breast NeoplasmsHRpos Breast Neoplasms+1 more
GBG Forschungs GmbH 107
Early research (Phase 1)Ended earlyNCT02561832
What this trial is testing

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT03344965
What this trial is testing

Olaparib In Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerInvasive Breast CancerSomatic Mutation Breast Cancer (BRCA1)+7 more
Beth Israel Deaconess Medical Center 114
Large-scale testing (Phase 3)Study completedNCT02282020
What this trial is testing

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 266
Testing effectiveness (Phase 2)Ended earlyNCT02034916
What this trial is testing

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)

Who this might be right for
Breast NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene Mutation
Pfizer 84
Testing effectiveness (Phase 2)Active Not RecruitingNCT03330847
What this trial is testing

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Who this might be right for
Metastatic Triple Negative Breast Cancer
AstraZeneca 273
Testing effectiveness (Phase 2)Ended earlyNCT03499353
What this trial is testing

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Who this might be right for
Early Breast Cancer
Pfizer 61
Not applicableStudy completedNCT05305001
What this trial is testing

Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico

Who this might be right for
Pancreatic CancerPancreatic Adenocarcinoma
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 107
Large-scale testing (Phase 3)Looking for participantsNCT06533384
What this trial is testing

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

Who this might be right for
Triple-negative Breast Cancer
Guangdong Provincial People's Hospital 310
Testing effectiveness (Phase 2)UnknownNCT04556292
What this trial is testing

A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer MetastaticBRCA 1 Gene MutationBRCA 2 Gene Mutation
Jiangxi Qingfeng Pharmaceutical Co. Ltd. 78
Testing effectiveness (Phase 2)WithdrawnNCT03933761
What this trial is testing

Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy

Who this might be right for
Ovarian CancerCarcinosarcoma
Australia New Zealand Gynaecological Oncology Group
Post-approval studies (Phase 4)Study completedNCT04330040
What this trial is testing

Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer

Who this might be right for
Ovarian CancerBreast Cancer
AstraZeneca 202
Testing effectiveness (Phase 2)Active Not RecruitingNCT02286687
What this trial is testing

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

Who this might be right for
Advanced Malignant NeoplasmATM Gene MutationBRCA1 Gene Mutation+5 more
M.D. Anderson Cancer Center 150
Not applicableStudy completedNCT05141708
What this trial is testing

Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m

Who this might be right for
Metastatic Breast CancerBreast Neoplasms
Pfizer 33
Large-scale testing (Phase 3)Study completedNCT03286842
What this trial is testing

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

Who this might be right for
HER2-ve Metastatic Breast CancerGermline BRCA1/2 MutationsSomatic BRCA1/2 Mutations
AstraZeneca 256
Large-scale testing (Phase 3)Study completedNCT01945775
What this trial is testing

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

Who this might be right for
Breast NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene Mutation
Pfizer 431
Not applicableLooking for participantsNCT07292246
What this trial is testing

A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)

Who this might be right for
Breast CancerBRCA 1 Gene MutationBRCA 2 Gene Mutation+5 more
Vasileios Kalles 15
Large-scale testing (Phase 3)Ended earlyNCT01905592
What this trial is testing

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

Who this might be right for
Neoplasms, BreastCarcinoma of BreastHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast+3 more
Tesaro, Inc. 216
Large-scale testing (Phase 3)Active Not RecruitingNCT02032823
What this trial is testing

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 1,836
Testing effectiveness (Phase 2)Looking for participantsNCT05485766
What this trial is testing

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsTriple Negative Breast CancerBreast Neoplasms+5 more
Okayama University 23
Load More Results